These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. Inzucchi SE Diabetes Care; 2017 Aug; 40(8):1128-1132. PubMed ID: 28733378 [TBL] [Abstract][Full Text] [Related]
4. [Therapeutic utility of biguanides in the treatment of NIDDM]. Fujimoto S Nihon Rinsho; 1999 Mar; 57(3):657-62. PubMed ID: 10199150 [TBL] [Abstract][Full Text] [Related]
6. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Scheen AJ; Paquot N Diabetes Metab; 2013 May; 39(3):179-90. PubMed ID: 23528671 [TBL] [Abstract][Full Text] [Related]
7. Metformin: from mechanisms of action to therapies. Foretz M; Guigas B; Bertrand L; Pollak M; Viollet B Cell Metab; 2014 Dec; 20(6):953-66. PubMed ID: 25456737 [TBL] [Abstract][Full Text] [Related]
8. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. Abdul-Ghani M; DeFronzo RA Diabetes Care; 2017 Aug; 40(8):1121-1127. PubMed ID: 28733377 [TBL] [Abstract][Full Text] [Related]
9. [Metformin and kidney]. Sessa C; Blanco J; Granata A; Fatuzzo P; Castellino P; Zanoli L G Ital Nefrol; 2016; 33(3):. PubMed ID: 27374392 [TBL] [Abstract][Full Text] [Related]
10. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. Saisho Y Endocr Metab Immune Disord Drug Targets; 2015; 15(3):196-205. PubMed ID: 25772174 [TBL] [Abstract][Full Text] [Related]
11. Biguanides and NIDDM. Bailey CJ Diabetes Care; 1992 Jun; 15(6):755-72. PubMed ID: 1600835 [TBL] [Abstract][Full Text] [Related]
13. Current understanding of metformin effect on the control of hyperglycemia in diabetes. An H; He L J Endocrinol; 2016 Mar; 228(3):R97-106. PubMed ID: 26743209 [TBL] [Abstract][Full Text] [Related]
14. A new perspective on the biguanide, metformin therapy in type 2 diabetes and lactic acidosis. Hotta N J Diabetes Investig; 2019 Jul; 10(4):906-908. PubMed ID: 31152685 [TBL] [Abstract][Full Text] [Related]
15. Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. Mary A; Hartemann A; Liabeuf S; Aubert CE; Kemel S; Salem JE; Cluzel P; Lenglet A; Massy ZA; Lalau JD; Mentaverri R; Bourron O; Kamel S Cardiovasc Diabetol; 2017 Feb; 16(1):24. PubMed ID: 28202017 [TBL] [Abstract][Full Text] [Related]
16. Metformin as first choice in oral diabetes treatment: the UKPDS experience. Holman R Journ Annu Diabetol Hotel Dieu; 2007; ():13-20. PubMed ID: 18613325 [TBL] [Abstract][Full Text] [Related]
17. Improving management of type 2 diabetes mellitus: 2. Biguanides. Quillen DM; Samraj G; Kuritzky L Hosp Pract (1995); 1999 Oct; 34(11):41-4. PubMed ID: 10887428 [No Abstract] [Full Text] [Related]
19. [How I treat ... with metformin a diabetic patient with moderate renal insufficiency]. Scheen AJ Rev Med Liege; 2013 Apr; 68(4):190-5. PubMed ID: 23755710 [TBL] [Abstract][Full Text] [Related]
20. Metformin: old wine in new bottle--evolving technology and therapy in diabetes. Joshi SR J Assoc Physicians India; 2005 Nov; 53():963-72. PubMed ID: 16515237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]